Join our upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.
Topics include:
- Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
- Common pitfalls on the path from R&D to biotech product commercialization
- Strategies for successful bioassay transfer and validation – the importance of standardization
Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.
Moderator: Stephan Holl, CEO Conscio Group
info@consciogroup.com
Follow us on LinkedIn